APA (7th ed.) Citation

O’Brien, T. J., Borghs, S., He, Q., Schulz, A., Yates, S., & Biton, V. (2020). Long‐term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: An up to 11‐year, open‐label, follow‐up trial. Epilepsia (Copenhagen), 61(4), 636-646. https://doi.org/10.1111/epi.16484

Chicago Style (17th ed.) Citation

O’Brien, Terence J., Simon Borghs, Qin He, Anne‐Liv Schulz, Stephen Yates, and Victor Biton. "Long‐term Safety, Efficacy, and Quality of Life Outcomes with Adjunctive Brivaracetam Treatment at Individualized Doses in Patients with Epilepsy: An Up to 11‐year, Open‐label, Follow‐up Trial." Epilepsia (Copenhagen) 61, no. 4 (2020): 636-646. https://doi.org/10.1111/epi.16484.

MLA (9th ed.) Citation

O’Brien, Terence J., et al. "Long‐term Safety, Efficacy, and Quality of Life Outcomes with Adjunctive Brivaracetam Treatment at Individualized Doses in Patients with Epilepsy: An Up to 11‐year, Open‐label, Follow‐up Trial." Epilepsia (Copenhagen), vol. 61, no. 4, 2020, pp. 636-646, https://doi.org/10.1111/epi.16484.